{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:23:57Z","timestamp":1780561437325,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The purpose of this study was to determine the prevalence of high disease activity as measured using the Ankylosing Spondylitis Disease Activity Score (ASDAS) in ankylosing spondylitis (AS) patients who nonetheless have low Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores after anti-tumor necrosis factor (TNF) treatment. Its clinical impact on anti-TNF survival was also investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a single-centre retrospective cohort study of AS patients having low BASDAI scores (&lt;\u20094) and available ASDAS-C-reactive protein (CRP) data after 3\u2009months of first-line anti-TNF treatment. Patients were grouped into high-ASDAS (\u2265 2.1) and low-ASDAS (&lt;\u20092.1) groups according to the ASDAS-CRP after 3\u2009months of anti-TNF treatment. Their characteristics were compared. And survival analyses were carried out using Kaplan\u2013Meier curves and log-rank test with the event being discontinuation of anti-TNF treatment due to lack\/loss of efficacy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 116 AS patients with low BASDAI scores after 3\u2009months of anti-TNF treatment, 38.8% were grouped into the high-ASDAS group. The high-ASDAS group tended to have greater disease activity after 9\u2009months of treatment (BASDAI 2.9 \u00b1 1.1 vs. 2.3 \u00b1 1.4, <jats:italic>p<\/jats:italic>=0.007; ASDAS-CRP 1.8 \u00b1 0.6 vs. 1.5 \u00b1 0.7, <jats:italic>p<\/jats:italic>=0.079; proportion of high ASDAS-CRP 27.8% vs. 13.8%, <jats:italic>p<\/jats:italic>=0.094) and greater risk of discontinuing anti-TNF treatment due to lack\/loss of efficacy than the low-ASDAS group (<jats:italic>p<\/jats:italic>=0.011).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A relatively high proportion of AS patients with low BASDAI scores had high ASDAS-CRP. These low-BASDAI\/high-ASDAS-CRP patients also had a greater risk for discontinuation of anti-TNF treatment due to low\/lack of efficacy than the low-ASDAS group. The use of the ASDAS-CRP alone or in addition to the BASDAI may improve the assessment of AS patients treated with anti-TNF agents.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12891-020-03941-8","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T08:04:11Z","timestamp":1612425851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study"],"prefix":"10.1186","volume":"22","author":[{"given":"Bora","family":"Nam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bon San","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hui","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Bin","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"3941_CR1","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(07)60635-7.","journal-title":"Lancet"},{"key":"3941_CR2","first-page":"S2","volume":"30","author":"JS Smolen","year":"2012","unstructured":"Smolen JS. Treat-to-target: rationale and strategies. Clin Exp Rheumatol. 2012;30:S2\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"3941_CR3","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1007\/s10067-016-3448-x","volume":"35","author":"L Gupta","year":"2016","unstructured":"Gupta L, Bhattacharya S, Agarwal V, Aggarwal A. Elevated levels of serum MRP8\/14 in ankylosing spondylitis: associated with peripheral arthritis and active disease. Clin Rheumatol. 2016;35:3075\u20139.","journal-title":"Clin Rheumatol"},{"key":"3941_CR4","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s10067-017-3938-5","volume":"37","author":"L Gupta","year":"2018","unstructured":"Gupta L, Bhattacharya S, Aggarwal A. Tenascin-C, a biomarker of disease activity in early ankylosing spondylitis. Clin Rheumatol. 2018;37:1401\u20135.","journal-title":"Clin Rheumatol"},{"key":"3941_CR5","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286\u201391.","journal-title":"J Rheumatol"},{"key":"3941_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/ard.2008.094870","volume":"68","author":"C Lukas","year":"2009","unstructured":"Lukas C, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:18\u201324. https:\/\/doi.org\/10.1136\/ard.2008.094870.","journal-title":"Ann Rheum Dis"},{"key":"3941_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77:3\u201317. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211734.","journal-title":"Ann Rheum Dis"},{"key":"3941_CR8","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, et al. 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71:1599\u2013613. https:\/\/doi.org\/10.1002\/art.41042.","journal-title":"Arthritis Rheumatol"},{"key":"3941_CR9","doi-asserted-by":"publisher","first-page":"e0131864","DOI":"10.1371\/journal.pone.0131864","volume":"10","author":"J-W Lee","year":"2015","unstructured":"Lee J-W, et al. Predictors of switching anti-tumor necrosis factor therapy in patients with ankylosing spondylitis. PLoS One. 2015;10:e0131864.","journal-title":"PLoS One"},{"key":"3941_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361\u20138. https:\/\/doi.org\/10.1002\/art.1780270401.","journal-title":"Arthritis Rheum"},{"key":"3941_CR11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.reuma.2013.12.006","volume":"10","author":"N Vastesaeger","year":"2014","unstructured":"Vastesaeger N, et al. ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy. Reumatol Clin. 2014;10:204\u20139.","journal-title":"Reumatol Clin"},{"key":"3941_CR12","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/rheumatology\/kes057","volume":"51","author":"KM Fagerli","year":"2012","unstructured":"Fagerli KM, et al. Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria. Rheumatology. 2012;51:1479\u201383.","journal-title":"Rheumatology"},{"key":"3941_CR13","doi-asserted-by":"publisher","first-page":"e001145","DOI":"10.1136\/rmdopen-2019-001145","volume":"6","author":"J Marona","year":"2020","unstructured":"Marona J, et al. Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI. RMD Open. 2020;6:e001145.","journal-title":"RMD Open"},{"key":"3941_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/14712598.2020.1694900","volume":"20","author":"J Tu\u017eil","year":"2020","unstructured":"Tu\u017eil J, et al. Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry. Exp Opin Biol Ther. 2020;20:183\u201392.","journal-title":"Exp Opin Biol Ther"},{"key":"3941_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631\u20137. https:\/\/doi.org\/10.1136\/ard.2009.123919.","journal-title":"Ann Rheum Dis"},{"key":"3941_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73:6\u201316. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203419.","journal-title":"Ann Rheum Dis"},{"key":"3941_CR17","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","volume":"73","author":"RF van Vollenhoven","year":"2014","unstructured":"van Vollenhoven RF, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73:958\u201367. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205139.","journal-title":"Ann Rheum Dis"},{"key":"3941_CR18","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1136\/annrheumdis-2016-209467","volume":"76","author":"U Kiltz","year":"2017","unstructured":"Kiltz U, et al. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2017;76:632\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209467.","journal-title":"Ann Rheum Dis"},{"key":"3941_CR19","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/rheumatology\/ker087","volume":"50","author":"M Xu","year":"2011","unstructured":"Xu M, et al. The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-\u03b1 inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China. Rheumatology. 2011;50:1466\u201372.","journal-title":"Rheumatology"},{"key":"3941_CR20","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/ard.2010.138883","volume":"70","author":"SJ Pedersen","year":"2011","unstructured":"Pedersen SJ, et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNF\u03b1 inhibitors. Ann Rheumatic Dis. 2011;70:1375\u201381.","journal-title":"Ann Rheumatic Dis"},{"key":"3941_CR21","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","volume":"73","author":"S Ramiro","year":"2014","unstructured":"Ramiro S, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheumatic Dis. 2014;73:1455\u201361.","journal-title":"Ann Rheumatic Dis"},{"key":"3941_CR22","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1136\/annrheumdis-2016-209209","volume":"75","author":"D Poddubnyy","year":"2016","unstructured":"Poddubnyy D, et al. High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. Ann Rheumatic Dis. 2016;75:2114\u20138.","journal-title":"Ann Rheumatic Dis"},{"key":"3941_CR23","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/art.33465","volume":"64","author":"D Poddubnyy","year":"2012","unstructured":"Poddubnyy D, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheumatism. 2012;64:1388\u201398.","journal-title":"Arthritis Rheumatism"},{"key":"3941_CR24","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.autrev.2009.01.005","volume":"8","author":"F Atzeni","year":"2009","unstructured":"Atzeni F, et al. Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev. 2009;8:431\u20137.","journal-title":"Autoimmun Rev"},{"key":"3941_CR25","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","volume":"45","author":"K Hyrich","year":"2006","unstructured":"Hyrich K, Watson K, Silman A, Symmons D. Predictors of response to anti-TNF-\u03b1 therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology. 2006;45:1558\u201365.","journal-title":"Rheumatology"},{"key":"3941_CR26","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12891-015-0620-4","volume":"16","author":"M Lorenzin","year":"2015","unstructured":"Lorenzin M, et al. Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskelet Disord. 2015;16:166.","journal-title":"BMC Musculoskelet Disord"},{"key":"3941_CR27","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","volume":"72","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor \u03b1 inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheumatic Dis. 2013;72:1149\u201355.","journal-title":"Ann Rheumatic Dis"},{"key":"3941_CR28","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/art.23333","volume":"59","author":"MS Heiberg","year":"2008","unstructured":"Heiberg MS, et al. The comparative one-year performance of anti\u2013tumor necrosis factor \u03b1 drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Care Res. 2008;59:234\u201340.","journal-title":"Arthritis Care Res"},{"key":"3941_CR29","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1136\/ard.2009.124446","volume":"69","author":"B Glintborg","year":"2010","unstructured":"Glintborg B, et al. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheumatic Dis. 2010;69:2002\u20138.","journal-title":"Ann Rheumatic Dis"},{"key":"3941_CR30","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1093\/rheumatology\/kez480","volume":"59","author":"IC Aranda-Valera","year":"2020","unstructured":"Aranda-Valera IC, et al. How to calculate the ASDAS based on C-reactive protein without individual questions from the BASDAI: the BASDAI-based ASDAS formula. Rheumatology. 2020;59:1545\u20139.","journal-title":"Rheumatology"},{"key":"3941_CR31","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s00296-020-04662-w","volume":"40","author":"T Sundaram","year":"2020","unstructured":"Sundaram T, Muhammed H, Aggarwal A, Gupta L. A prospective study of novel disease activity indices for ankylosing spondylitis. Rheumatol Int. 2020;40:1843\u20139.","journal-title":"Rheumatol Int"},{"key":"3941_CR32","doi-asserted-by":"publisher","unstructured":"Ibanez Vodnizza SE, van Bentum RE, Valenzuela O, van der Horst-Bruinsma IE. Patients with axial spondyloarthritis report significant differences between men and women and high impact of the disease: Large websurvey analysis. Joint Bone Spine. 2020. https:\/\/doi.org\/10.1016\/j.jbspin.2020.02.004.","DOI":"10.1016\/j.jbspin.2020.02.004"},{"key":"3941_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11926-018-0744-2","volume":"20","author":"T Rusman","year":"2018","unstructured":"Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE. Gender Differences in Axial Spondyloarthritis: Women Are Not So Lucky. Curr Rheumatol Rep. 2018;20:35. https:\/\/doi.org\/10.1007\/s11926-018-0744-2.","journal-title":"Curr Rheumatol Rep"},{"key":"3941_CR34","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10067-011-1819-x","volume":"31","author":"YI Yacoub","year":"2012","unstructured":"Yacoub YI, Amine B, Laatiris A, Hajjaj-Hassouni N. Gender and disease features in Moroccan patients with ankylosing spondylitis. Clin Rheumatol. 2012;31:293\u20137.","journal-title":"Clin Rheumatol"},{"key":"3941_CR35","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s10067-013-2439-4","volume":"34","author":"A Shahlaee","year":"2015","unstructured":"Shahlaee A, et al. Gender differences in Iranian patients with ankylosing spondylitis. Clin Rheumatol. 2015;34:285\u201393.","journal-title":"Clin Rheumatol"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-020-03941-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12891-020-03941-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-020-03941-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T08:05:09Z","timestamp":1612425909000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-020-03941-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3941"],"URL":"https:\/\/doi.org\/10.1186\/s12891-020-03941-8","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,4]]},"assertion":[{"value":"5 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed according to the guidelines of the Helsinki Declaration and approved by the institutional review board of Hanyang University Hospital (IRB file No. HYUH 2019\u201309-016). Patient consent to participate was waived as this is a retrospective study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}